Joshua Hansen

6PUBLICATIONS
32CO-AUTHORS
Biologically active moleculesCheminformatics and quantitative structure-activity relationshipsCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicineCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2026
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365.

|Aug 11, 2025
Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.

Surendra Nayak, John D Norris, Massimo Ammirante

|Aug 06, 2021
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.

Patrick Papa, Brandon Whitefield, Deborah S Mortensen

|Feb 16, 2021
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.

Joshua D Hansen, Matthew Correa, Matt Alexander

|Mar 05, 2020
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.

Joshua D Hansen, Matthew Correa, Mark A Nagy

|Mar 31, 2017
Protein Degradation via CRL4<sup>CRBN</sup> Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

Joshua D Hansen, Kevin Condroski, Matthew Correa

Pageof 1

Frequent Collaborators

3 joint publications

Deborah S Mortensen

2 joint publications

Lawrence G Hamann

2 joint publications

Shuichan Xu

2 joint publications

Brian E Cathers